SCHEMBL3595946

SCHEMBL3595946

O=C(/C=C/c1cccc(F)c1O)c1cccnc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 8/20 0.62
CYP1A2 P05177 8/20 0.62
CYP1B1 Q16678 8/20 0.62
MAPT P10636 3/20 0.61
ALDH1A1 P00352 2/20 0.61
LMNA P02545 2/20 0.61
KMT2A Q03164 2/20 0.61
HPGD P15428 1/20 0.61
KDM4E B2RXH2 1/20 0.61
PKM P14618 1/20 0.61
CYP3A4 P08684 6/20 0.57
CYP2D6 P10635 6/20 0.57
MCL1 Q07820 1/20 0.57
APP P05067 1/20 0.53
GSK3B P49841 1/20 0.53
NTSR1 P30989 1/20 0.52
USP2 O75604 1/20 0.50
CAPN1 P07384 1/20 0.49
CTSL P07711 1/20 0.49
CTSB P07858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595951 1.00 CYP1A1 (0.62) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL17824546 0.82 LMNA (0.77) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL17824538 0.82 LMNA (0.77) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL3600603 0.81 CYP1A1 (0.59) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL3600600 0.81 CYP1A1 (0.59) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL3597959 0.80 MAPT (0.72) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL3597965 0.80 MAPT (0.72) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL3598073 0.78 APP (0.64) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL3598076 0.78 APP (0.64) CYP1A1CYP1A2CYP1B1MAPTALDH1A1
SCHEMBL3596015 0.77 ALDH1A1 (0.60) CYP1A1CYP1A2CYP1B1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795249-B2 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-14 US disclosed
US-7795249-B2 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-14 US disclosed
US-7795249-B2 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-14 US disclosed
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-17 US disclosed
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-17 US disclosed
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-17 US disclosed
WO-2008079277-A1 CERTAIN PYRAZOLINE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MAP3K5, MAP4K5, MAP3K20 CYP1A1 3298/4885CYP1A2 2231/4885CYP1B1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.